DefinePK

Abstract

Purpose: To evaluate the efficacy and safety of subconjunctival Bevacizumab on primary and recurrent Pterygium.
Materials and Method: 35 patients with either Primary or recurrent Pterygium (extending on corneal surface) were given a single subconjunctival injection of 1.25mg/0.05ml of Bevacizumab (Avastin) and were evaluated for periodic clinical results at Day 1, 2weeks, 4 weeks and monthly for 3 month. Ophthalmic evaluation including Snellen’s visual acuity, intra-ocular pressure and complete examination was done at baseline and on every follow up. Digital photograph of eyes with Pterygium were taken at baseline and at each follow-up and analyzed. Size and height of tissue on digital photograph was measured by using Universal desktop ruler version 3.5.
Results: Visual acuity and intraocular pressure remained stable.1-2mm regression in size of Pterygium from corneal surface occurred at 2 weeks post injection but reversed again to pre injection state at 1 month follow up. Mean size (9.70+1.55mm) and height (5.24+0.9mm) remained the same at baseline and at last follow up (3 month). No progression of Pterygium occurred. No ocular or systemic adverse effects of Bevacizumab were observed.
Conclusion: Short term results suggest that subconjunctival bevacizumab injection is well tolerated and cause a partial temporary regression in size of Pterygium. However, it does not cause complete regression of corneal vessels in Pterygium.